vs
Side-by-side financial comparison of CorMedix Inc. (CRMD) and ONESPAWORLD HOLDINGS Ltd (OSW). Click either name above to swap in a different company.
ONESPAWORLD HOLDINGS Ltd is the larger business by last-quarter revenue ($242.1M vs $128.6M, roughly 1.9× CorMedix Inc.). CorMedix Inc. produced more free cash flow last quarter ($92.7M vs $14.9M).
CorMedix Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing novel therapeutic products for the prevention and treatment of infectious, inflammatory and cardiorenal diseases. Its lead candidate targets catheter-related bloodstream infections, serving critical care and chronic dialysis patient populations primarily across North America and European markets.
CRMD vs OSW — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $128.6M | $242.1M |
| Net Profit | — | $12.1M |
| Gross Margin | 83.4% | — |
| Operating Margin | 46.0% | 6.8% |
| Net Margin | — | 5.0% |
| Revenue YoY | — | 11.5% |
| Net Profit YoY | — | -16.2% |
| EPS (diluted) | $0.20 | $0.12 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $128.6M | $242.1M | ||
| Q3 25 | $104.3M | $258.5M | ||
| Q2 25 | $39.7M | $240.7M | ||
| Q1 25 | $39.1M | $219.6M | ||
| Q4 24 | — | $217.2M | ||
| Q3 24 | — | $241.7M | ||
| Q2 24 | — | $224.9M | ||
| Q1 24 | — | $211.2M |
| Q4 25 | — | $12.1M | ||
| Q3 25 | $108.6M | $24.3M | ||
| Q2 25 | $19.8M | $19.9M | ||
| Q1 25 | $20.6M | $15.3M | ||
| Q4 24 | — | $14.4M | ||
| Q3 24 | — | $21.6M | ||
| Q2 24 | — | $15.8M | ||
| Q1 24 | — | $21.2M |
| Q4 25 | 83.4% | — | ||
| Q3 25 | 89.3% | — | ||
| Q2 25 | 95.3% | — | ||
| Q1 25 | 95.9% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | 46.0% | 6.8% | ||
| Q3 25 | 49.2% | 10.2% | ||
| Q2 25 | 49.2% | 9.2% | ||
| Q1 25 | 51.5% | 7.7% | ||
| Q4 24 | — | 7.9% | ||
| Q3 24 | — | 10.3% | ||
| Q2 24 | — | 8.4% | ||
| Q1 24 | — | 8.0% |
| Q4 25 | — | 5.0% | ||
| Q3 25 | 104.1% | 9.4% | ||
| Q2 25 | 49.9% | 8.3% | ||
| Q1 25 | 52.8% | 7.0% | ||
| Q4 24 | — | 6.6% | ||
| Q3 24 | — | 8.9% | ||
| Q2 24 | — | 7.0% | ||
| Q1 24 | — | 10.0% |
| Q4 25 | $0.20 | $0.12 | ||
| Q3 25 | $1.26 | $0.23 | ||
| Q2 25 | $0.28 | $0.19 | ||
| Q1 25 | $0.30 | $0.15 | ||
| Q4 24 | — | $0.13 | ||
| Q3 24 | — | $0.20 | ||
| Q2 24 | — | $0.15 | ||
| Q1 24 | — | $0.21 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $148.5M | $16.3M |
| Total DebtLower is stronger | — | $84.0M |
| Stockholders' EquityBook value | $405.3M | $542.6M |
| Total Assets | $826.1M | $707.1M |
| Debt / EquityLower = less leverage | — | 0.15× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $148.5M | $16.3M | ||
| Q3 25 | $55.7M | $29.6M | ||
| Q2 25 | $190.7M | $35.0M | ||
| Q1 25 | $77.5M | $22.6M | ||
| Q4 24 | — | $57.4M | ||
| Q3 24 | — | $48.8M | ||
| Q2 24 | — | $62.5M | ||
| Q1 24 | — | $65.4M |
| Q4 25 | — | $84.0M | ||
| Q3 25 | — | $85.2M | ||
| Q2 25 | — | $96.2M | ||
| Q1 25 | — | $97.4M | ||
| Q4 24 | — | $98.6M | ||
| Q3 24 | — | $98.7M | ||
| Q2 24 | — | $123.8M | ||
| Q1 24 | — | $138.6M |
| Q4 25 | $405.3M | $542.6M | ||
| Q3 25 | $374.1M | $552.8M | ||
| Q2 25 | $220.6M | $548.3M | ||
| Q1 25 | $114.9M | $530.6M | ||
| Q4 24 | — | $554.5M | ||
| Q3 24 | — | $540.1M | ||
| Q2 24 | — | $532.7M | ||
| Q1 24 | — | $515.5M |
| Q4 25 | $826.1M | $707.1M | ||
| Q3 25 | $750.9M | $732.6M | ||
| Q2 25 | $252.6M | $731.8M | ||
| Q1 25 | $149.6M | $708.7M | ||
| Q4 24 | — | $746.4M | ||
| Q3 24 | — | $734.0M | ||
| Q2 24 | — | $756.8M | ||
| Q1 24 | — | $763.6M |
| Q4 25 | — | 0.15× | ||
| Q3 25 | — | 0.15× | ||
| Q2 25 | — | 0.18× | ||
| Q1 25 | — | 0.18× | ||
| Q4 24 | — | 0.18× | ||
| Q3 24 | — | 0.18× | ||
| Q2 24 | — | 0.23× | ||
| Q1 24 | — | 0.27× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $94.5M | $20.0M |
| Free Cash FlowOCF − Capex | $92.7M | $14.9M |
| FCF MarginFCF / Revenue | 72.1% | 6.2% |
| Capex IntensityCapex / Revenue | 1.3% | 2.1% |
| Cash ConversionOCF / Net Profit | — | 1.65× |
| TTM Free Cash FlowTrailing 4 quarters | $172.8M | $68.4M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $94.5M | $20.0M | ||
| Q3 25 | $30.9M | $33.2M | ||
| Q2 25 | $30.0M | $20.3M | ||
| Q1 25 | $19.7M | $10.1M | ||
| Q4 24 | — | $16.6M | ||
| Q3 24 | — | $28.6M | ||
| Q2 24 | — | $18.7M | ||
| Q1 24 | — | $15.0M |
| Q4 25 | $92.7M | $14.9M | ||
| Q3 25 | $30.4M | $27.6M | ||
| Q2 25 | $30.0M | $17.6M | ||
| Q1 25 | $19.7M | $8.4M | ||
| Q4 24 | — | $13.2M | ||
| Q3 24 | — | $27.5M | ||
| Q2 24 | — | $17.6M | ||
| Q1 24 | — | $13.7M |
| Q4 25 | 72.1% | 6.2% | ||
| Q3 25 | 29.1% | 10.7% | ||
| Q2 25 | 75.4% | 7.3% | ||
| Q1 25 | 50.5% | 3.8% | ||
| Q4 24 | — | 6.1% | ||
| Q3 24 | — | 11.4% | ||
| Q2 24 | — | 7.8% | ||
| Q1 24 | — | 6.5% |
| Q4 25 | 1.3% | 2.1% | ||
| Q3 25 | 0.5% | 2.2% | ||
| Q2 25 | 0.1% | 1.1% | ||
| Q1 25 | 0.0% | 0.8% | ||
| Q4 24 | — | 1.5% | ||
| Q3 24 | — | 0.5% | ||
| Q2 24 | — | 0.5% | ||
| Q1 24 | — | 0.6% |
| Q4 25 | — | 1.65× | ||
| Q3 25 | 0.28× | 1.36× | ||
| Q2 25 | 1.51× | 1.02× | ||
| Q1 25 | 0.96× | 0.66× | ||
| Q4 24 | — | 1.15× | ||
| Q3 24 | — | 1.33× | ||
| Q2 24 | — | 1.19× | ||
| Q1 24 | — | 0.71× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CRMD
| Acquisition Of Melinta | $52.9M | 41% |
| Melinta Portfolio | $45.5M | 35% |
| Other | $18.6M | 14% |
| Contract Revenue | $7.4M | 6% |
| BARDA Agreement | $4.2M | 3% |
OSW
| Services | $197.3M | 82% |
| Products | $44.8M | 18% |
